Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Immunic Inc has a consensus price target of $14.36 based on the ratings of 12 analysts. The high is $35 issued by Aegis Capital on August 8, 2022. The low is $5 issued by B. Riley Securities on May 23, 2025. The 3 most-recent analyst ratings were released by D. Boral Capital, D. Boral Capital, and B. Riley Securities on June 5, 2025, May 29, 2025, and May 23, 2025, respectively. With an average price target of $8.33 between D. Boral Capital, D. Boral Capital, and B. Riley Securities, there's an implied 992.18% upside for Immunic Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/05/2025 | Buy Now | 1210.62% | D. Boral Capital | Jason Kolbert46% | $10 → $10 | Maintains | Buy | Get Alert |
05/29/2025 | Buy Now | 1210.62% | D. Boral Capital | Jason Kolbert46% | $17 → $10 | Maintains | Buy | Get Alert |
05/23/2025 | Buy Now | 555.31% | B. Riley Securities | William Woods26% | $6 → $5 | Reiterates | Buy → Buy | Get Alert |
05/01/2025 | Buy Now | 1210.62% | HC Wainwright & Co. | Matthew Caufield38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
04/30/2025 | Buy Now | 2128.05% | D. Boral Capital | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
04/16/2025 | Buy Now | 686.37% | B. Riley Securities | William Woods26% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
04/15/2025 | Buy Now | 1210.62% | HC Wainwright & Co. | Matthew Caufield38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
04/10/2025 | Buy Now | 2128.05% | D. Boral Capital | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
04/01/2025 | Buy Now | 2128.05% | D. Boral Capital | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
03/25/2025 | Buy Now | — | William Blair | Myles Minter38% | — | Initiates | → Outperform | Get Alert |
02/26/2025 | Buy Now | 2128.05% | D. Boral Capital | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
02/21/2025 | Buy Now | 1210.62% | HC Wainwright & Co. | Matthew Caufield38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
02/20/2025 | Buy Now | 2128.05% | D. Boral Capital | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
01/07/2025 | Buy Now | 2128.05% | D. Boral Capital | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
11/25/2024 | Buy Now | 1210.62% | HC Wainwright & Co. | Matthew Caufield38% | → $10 | Initiates | → Buy | Get Alert |
11/07/2024 | Buy Now | 2128.05% | EF Hutton | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
10/22/2024 | Buy Now | 2128.05% | EF Hutton | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
09/18/2024 | Buy Now | 2128.05% | EF Hutton | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
09/16/2024 | Buy Now | 2128.05% | EF Hutton | Jason Kolbert46% | → $17 | Initiates | → Buy | Get Alert |
09/09/2024 | Buy Now | 555.31% | Leerink Partners | Faisal Khurshid38% | → $5 | Assumes | → Outperform | Get Alert |
08/27/2024 | Buy Now | 686.37% | B. Riley Securities | William Woods26% | → $6 | Initiates | → Buy | Get Alert |
07/16/2024 | Buy Now | 3569.72% | Piper Sandler | Yasmeen Rahimi56% | $28 → $28 | Reiterates | Overweight → Overweight | Get Alert |
04/05/2024 | Buy Now | 1210.62% | Brookline Capital | Tyler Bussian22% | → $10 | Initiates | → Buy | Get Alert |
10/10/2023 | Buy Now | 817.43% | Wedbush | Andreas Argyrides71% | $5 → $7 | Maintains | Outperform | Get Alert |
07/27/2023 | Buy Now | 555.31% | Wedbush | Andreas Argyrides71% | → $5 | Reiterates | Outperform → Outperform | Get Alert |
01/31/2023 | Buy Now | 555.31% | Wedbush | Andreas Argyrides71% | → $5 | Assumes | → Outperform | Get Alert |
10/21/2022 | Buy Now | 555.31% | SVB Leerink | Thomas Smith34% | $9 → $5 | Downgrade | Outperform → Market Perform | Get Alert |
09/19/2022 | Buy Now | 3307.6% | HC Wainwright & Co. | Gobind Singh20% | → $26 | Assumes | → Buy | Get Alert |
08/08/2022 | Buy Now | 4487.16% | Aegis Capital | Nathan Weinstein31% | $40 → $35 | Maintains | Buy | Get Alert |
The latest price target for Immunic (NASDAQ:IMUX) was reported by D. Boral Capital on June 5, 2025. The analyst firm set a price target for $10.00 expecting IMUX to rise to within 12 months (a possible 1210.62% upside). 22 analyst firms have reported ratings in the last year.
The latest analyst rating for Immunic (NASDAQ:IMUX) was provided by D. Boral Capital, and Immunic maintained their buy rating.
There is no last upgrade for Immunic
The last downgrade for Immunic Inc happened on October 21, 2022 when SVB Leerink changed their price target from $9 to $5 for Immunic Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunic was filed on June 5, 2025 so you should expect the next rating to be made available sometime around June 5, 2026.
While ratings are subjective and will change, the latest Immunic (IMUX) rating was a maintained with a price target of $10.00 to $10.00. The current price Immunic (IMUX) is trading at is $0.76, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.